Avid Bioservices Inc. (CDMO) Financial Statements (2024 and earlier)

Company Profile

Business Address 14191 MYFORD ROAD
TUSTIN, CA 92780
State of Incorp. DE
Fiscal Year End April 30
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

4/30/2024
Q4
1/31/2024
Q3
10/31/2023
Q2
7/31/2023
Q1
4/30/2023
Q4
1/31/2023
Q3
10/31/2022
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments35,50838,92424,89838,54259,91677,292
Cash and cash equivalents30,70831,42424,89838,54259,91677,292
Short-term investments4,8007,500    
Receivables18,53813,37916,20918,29814,82620,580
Inventory, net of allowances, customer advances and progress billings34,56838,58340,86643,90845,10239,061
Inventory34,56838,58340,86643,90845,10239,061
Other undisclosed current assets14,97513,31916,34611,70312,4999,008
Total current assets:103,589104,20598,319112,451132,343145,941
Noncurrent Assets
Operating lease, right-of-use asset41,56741,97342,37442,77234,46335,373
Property, plant and equipment187,518187,174182,299177,770164,292139,386
Deferred income tax assets 117,844116,617114,238113,751114,580116,647
Other noncurrent assets4,7094,6734,7574,4734,4024,153
Other undisclosed noncurrent assets   350350350350
Total noncurrent assets:351,638350,437344,018339,116318,087295,909
TOTAL ASSETS:455,227454,642442,337451,567450,430441,850
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities23,62127,02827,48033,37344,79235,342
Employee-related liabilities6,007
Accounts payable19,51422,78422,81324,59336,39223,328
Accrued liabilities4,1074,2444,6678,7808,4006,007
Deferred revenue52,94546,43733,01937,35237,75048,446
Debt 141,421 539140,623524 
Other liabilities3,5902,2092,2962,4401,7531,485
Other undisclosed current liabilities1,3101,2637231,3582,500(2,896)
Total current liabilities:222,88776,93764,057215,14687,31982,377
Noncurrent Liabilities
Long-term debt and lease obligation7,475148,994142,3121,562142,057178,278
Long-term debt, excluding current maturities 141,154140,888 140,359140,097
Finance lease, liability7,4757,8401,4241,5621,6981,831
Liabilities, other than long-term debt44,69545,03645,37045,69035,659 
Operating lease, liability44,69545,03645,37045,69035,65936,350
Other undisclosed noncurrent liabilities     (36,350)
Total noncurrent liabilities:52,170194,030187,68247,252177,716178,278
Total liabilities:275,057270,967251,739262,398265,035260,655
Equity
Equity, attributable to parent180,170183,675190,598189,169185,395181,195
Common stock636363636262
Additional paid in capital628,874626,031623,445620,224615,841612,102
Accumulated deficit(448,767)(442,419)(432,910)(431,118)(430,508)(430,969)
Total equity:180,170183,675190,598189,169185,395181,195
TOTAL LIABILITIES AND EQUITY:455,227454,642442,337451,567450,430441,850

Income Statement (P&L) ($ in thousands)

4/30/2024
Q4
1/31/2024
Q3
10/31/2023
Q2
7/31/2023
Q1
4/30/2023
Q4
1/31/2023
Q3
10/31/2022
Q2
Revenues33,81525,39537,72639,79938,01834,757
Cost of revenue
(Cost of Goods and Services Sold)
(31,432)(30,060)(33,626)(31,408)(28,193)(30,610)
Gross profit:2,383(4,665)4,1008,3919,8254,147
Operating expenses(6,382)(6,557)(6,263)(7,559)(7,107)(6,831)
Operating income (loss):(3,999)(11,222)(2,163)8322,718(2,684)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(2,184)140258 432 
Interest and debt expense(875)(805)(775)(1,172)(620)(703)
Other undisclosed loss from continuing operations before equity method investments, income taxes    (627)  
Income (loss) from continuing operations before equity method investments, income taxes:(7,058)(11,887)(2,680)(967)2,530(3,387)
Other undisclosed income (loss) from continuing operations before income taxes   1,002 145
Income (loss) from continuing operations before income taxes:(7,058)(11,887)(2,680)352,530(3,242)
Income tax expense (benefit)1,0522,378587(645)(2,069)2,086
Income (loss) from continuing operations:(6,006)(9,509)(2,093)(610)461(1,156)
Loss before gain (loss) on sale of properties:(1,156)
Net income (loss) available to common stockholders, diluted:(6,006)(9,509)(2,093)(610)461(1,156)

Comprehensive Income ($ in thousands)

4/30/2024
Q4
1/31/2024
Q3
10/31/2023
Q2
7/31/2023
Q1
4/30/2023
Q4
1/31/2023
Q3
10/31/2022
Q2
Net income (loss):(6,006)(9,509)(2,093)(610)461(1,156)
Comprehensive income (loss), net of tax, attributable to parent:(6,006)(9,509)(2,093)(610)461(1,156)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: